Craig Venter J. Craig Venter in conversation with SynBioBeta founder John Cumbers about the state of the synthetic biology industry.
Home » Health and medicine » SynBioBeta State of the Industry Town Hall with J. Craig Venter

SynBioBeta State of the Industry Town Hall with J. Craig Venter

In 2000, synthetic biology visionary J. Craig Venter completed the first draft of the human genome. Ten years later, his team created the first synthetic cell. Craig will join SynBioBeta founder John Cumbers for a conversation about the state of the synthetic biology industry. In light of SARS-CoV-2, we’ll also ask what the coronavirus pandemic means to innovation, our community, and our relationship with society. We’ll discuss:

  • How synthetic biology has surpassed or fallen short of expectations
  • The JCVI’s efforts to create a COVID-19 viral epitope map for vaccine development
  • How COVID-19 is changing how synthetic biology is regarded by public stakeholders
  • Three trends Craig sees in the next 5 years

Tuesday, March 31, 2020, 8 am Pacific

J. Craig Venter is known for leading the first draft sequence of the human genome. He later assembled the first team to transfect a cell with a synthetic chromosome. Venter founded Celera Genomics, The Institute for Genomic Research (TIGR) and the J. Craig Venter Institute (JCVI), where he currently serves as CEO. He was the co-founder of Human Longevity Inc. and Synthetic Genomics. He was listed on Time magazine’s 2007 and 2008 Time 100 list of the most influential people in the world.

8
Kevin Costa

Kevin Costa

As Editor and Program Manager, Kevin leads SynBioBeta's digital media content, with the goal of telling the story of the people, companies, and ideas shaping the future with biology. Before joining SynBioBeta, Kevin managed the Synthetic Biology Engineering Research Center. His interests include public engagement, science writing, community building, and bikes!

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.